Inhibition of PCSK9 with evolocumab reduces the risk of first major cardiovascular events by 25% in high-risk patients who have not experienced a prior heart attack or stroke.

Study: Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.

The study tested evolocumab in people at high risk for heart problems but who hadn’t had a heart attack or stroke, and found it reduced their risk of such events by 25%, just like the claim says.

Study: Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

This study showed that people with high cholesterol and diabetes who had never had a heart attack or stroke were 31% less likely to have a first major heart problem when taking evolocumab, which supports the claim that the drug lowers first-time heart risks by about 25%.

Study: Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

The study shows that adding evolocumab to statins helps prevent serious heart and stroke problems in high-risk patients, including those who haven’t had a heart attack or stroke before.

Study: Primary and secondary prevention of stroke and cardiovascular events using evolocumab and alirocumab: Meta-analysis of randomized controlled trials.

The study shows that evolocumab helps prevent heart problems in high-risk patients who haven’t had a heart attack or stroke, but the benefit is about 18%, not 25% as claimed.